Cited by 4,792Nanoparticle-Based Drug DeliveryUltrasound and Hyperthermia ApplicationsRNA Interference and Gene Delivery

The DOI matches its Crossref record; 127 of the 140 references it cites were found in a registry or an index.

Doxil® — The first FDA-approved nano-drug: Lessons learned

Barenholz, Yechezkel (Chezy)·2012·Journal of Controlled Release

DOI 10.1016/j.jconrel.2012.03.020

Open this paper in CoChat — free account

Abstract

Doxil®, the first FDA-approved nano-drug (1995), is based on three unrelated principles: (i) prolonged drug circulation time and avoidance of the RES due to the use of PEGylated nano-liposomes; (ii) high and stable remote loading of doxorubicin driven by a transmembrane ammonium sulfate gradient, which also allows for drug release at the tumor; and (iii) having the liposome lipid bilayer in a "liquid ordered" phase composed of the high-T(m) (53 °C) phosphatidylcholine, and cholesterol. Due to the EPR effect, Doxil is "passively targeted" to tumors and its doxorubicin is released and becomes available to tumor cells by as yet unknown means. This review summarizes historical and scientific perspectives of Doxil development and lessons learned from its development and 20 years of its use. It demonstrates the obligatory need for applying an understanding of the cross talk between physicochemical, nano-technological, and biological principles. However, in spite of the large reward, ~2 years after Doxil-related patents expired, there is still no FDA-approved generic "Doxil" available.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2012.03.020

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,868
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,344
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
Klibanov, A. L., Maruyama, K., Torchilin, V. P., & Huang, L. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81016-h · Cited by 2,030
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Pharmacokinetics of Pegylated Liposomal Doxorubicin
Gabizón, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,639
Self-citation
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Self-citation
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,357
Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.
Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212

Flagged first, then by citations

Show all 140 references

13 of the 140 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Amselem, 1993, A large-scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use, vol. 1, 501
Barenholz, 1993, Quality control assays in the development and clinical use of liposome-based formulations, vol. 1, 527
Poste, 1983, Liposome targeting in vivo: problems and opportunities, Biol. Cell, 47, 19

Sorted by citations

Items 901–1,000 of 1,008

Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer
Dasa, S. S. K., Diakova, G. B., Suzuki, R., Mills, A. M., Gutknecht, M. F., Klibanov, A. L., Slack‐Davis, J. K., & Kelly, K. A. (2018) · Theranostics · doi:10.7150/thno.23050 · Cited by 72
Advanced architectures in the design of responsive polymers for cancer nanomedicine
Wagner, A. M., Spencer, D. S., & Peppas, N. A. (2018) · Journal of Applied Polymer Science · doi:10.1002/app.46154 · Cited by 74
Multimodal doxorubicin loaded magnetic nanoparticles for VEGF targeted theranostics of breast cancer
Semkina, A. S., Abakumov, M. A., Skorikov, A. S., Abakumova, T. O., Melnikov, P., Grinenko, N. F., Cherepanov, S. A., Vishnevskiy, D. A., Naumenko, V., Ionova, K., et al. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.04.019 · Cited by 72
Biodistribution of TAT or QLPVM coupled to receptor targeted liposomes for delivery of anticancer therapeutics to brain in vitro and in vivo
Lakkadwala, S., Rodrigues, B. D. S., Sun, C., & Singh, J. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102112 · Cited by 72
Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small cell lung cancer
Shahriari, M., Taghdisi, S. M., Abnous, K., Ramezani, M., & Alibolandi, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.039 · Cited by 71
Recent progress in stimuli-responsive nanosystems for inducing immunogenic cell death
Banstola, A., Poudel, K., Kim, J. O., Jeong, J., & Yook, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.038 · Cited by 71
Nanotherapeutics for pulmonary drug delivery: An emerging approach to overcome respiratory diseases
Kole, E. B., Jadhav, K., Shirsath, N. R., Dudhe, P. B., Verma, R. K., Chatterjee, A., & Naik, J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104261 · Cited by 76
Nanoparticles in Medicine: Current Status in Cancer Treatment
Pavelić, K., Pavelić, S. K., Bulog, A., Agaj, A., Rojnić, B., Čolić, M., & Trivanović, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612827 · Cited by 73
An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery
Xie, Y., Ding, Y., Sun, D., Wang, G., Hongge, Y., Xu, H., Wang, Z., & Chen, J. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s92519 · Cited by 71
Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery
Xu, H., Hu, M., Xiu, Y., Li, Y., Fu, Y., Zhou, X., Zhang, D., & Li, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.030 · Cited by 71
The theranostic path to personalized nanomedicine
Theek, B., Rizzo, L. Y., Ehling, J., Kiessling, F. M., & Lammers, T. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0051-5 · Cited by 71
Aptamer-based liposomes improve specific drug loading and release
Plourde, K., Derbali, R. M., Desrosiers, A., Dubath, C., Vallée‐Bélisle, A., & Chain, J. L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.026 · Cited by 71
Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies
Nikpoor, A. R., Tavakkol‐Afshari, J., Sadri, K., Jalali, S. A., & Jaafari, M. R. (2017) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2017.08.010 · Cited by 71
Recombinant Synthesis of Hybrid Lipid–Peptide Polymer Fusions that Self‐Assemble and Encapsulate Hydrophobic Drugs
Luginbuhl, K. M., Mozhdehi, D., Dzuricky, M. J., Yousefpour, P., Huang, F. C., Mayne, N. R., Buehne, K. L., & Chilkoti, A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201704625 · Cited by 71
Stealth coatings for nanoparticles
Hadjesfandiari, N., & Anilkumar, P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101750-0.00013-1 · Cited by 75
Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin
Liu, F., Mu, J., & Xing, B. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150302115411 · Cited by 70
Human Biomolecular Corona of Liposomal Doxorubicin: The Overlooked Factor in Anticancer Drug Delivery
Caracciolo, G., Palchetti, S., Digiacomo, L., Chiozzi, R. Z., Capriotti, A. L., Amenitsch, H. W., Tentori, P. M., Palmieri, V., Papi, M., Cardarelli, F., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b04962 · Cited by 70
Recent advances on microneedle arrays-mediated technology in cancer diagnosis and therapy
Alimardani, V., Abolmaali, S. S., Tamaddon, A. M., & Ashfaq, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00819-z · Cited by 70
Continuous-Flow Production of Liposomes with a Millireactor under Varying Fluidic Conditions
Yanar, F., Mosayyebi, A., Nastruzzi, C., Carugo, D., & Zhang, X. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111001 · Cited by 70
Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer
Sheikh, A., Alhakamy, N. A., Md, S., & Kesharwani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.803304 · Cited by 71
Application of lipid nanovesicle drug delivery system in cancer immunotherapy
Ding, Y., Wang, L., Li, H., Miao, F., Zhang, Z., Hu, C., Yu, W., Tang, Q., & Shao, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01429-2 · Cited by 70
Enzyme-responsive liposomes for controlled drug release
Wei, Y., Lv, J., Zhu, S., Wang, S., Su, J., & Xu, C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104014 · Cited by 70
Mild Hyperthermia Enhances Transport of Liposomal Gemcitabine and Improves In Vivo Therapeutic Response
Kirui, D. K., Celia, C., Molinaro, R., Bansal, S. S., Cosco, D., Fresta, M., Shen, H., & Mauro Ferrari, B. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201400738 · Cited by 70
Horizon Scan of Nanomedicinal Products
Noorlander, C. W., Kooi, M., Oomen, A. G., Park, M. V. D. Z., Vandebriel, R. J., & Geertsma, R. E. (2015) · Nanomedicine · doi:10.2217/nnm.15.21 · Cited by 70
Overcoming multidrug resistance with nanomedicines
Ganoth, A., Merimi, K. C., & Peer, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.960920 · Cited by 72
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer
Zhang, N., Zhang, B., Gong, X., Wang, T., Liu, Y., & Yang, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s104119 · Cited by 70
pH and NIR-light-responsive magnetic iron oxide nanoparticles for mitochondria-mediated apoptotic cell death induced by chemo-photothermal therapy
Oh, Y., Je, J., Santhamoorthy, M., Seo, H., & Cho, W. H. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.014 · Cited by 70
Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives
Lorenzo, G. D., Ricci, G., Severini, G. M., Romano, F., & Biffi, S. (2018) · Theranostics · doi:10.7150/thno.26345 · Cited by 70
Targeted chemotherapy for subcutaneous and orthotopic non-small cell lung tumors with cyclic RGD-functionalized and disulfide-crosslinked polymersomal doxorubicin
Zou, Y., Wei, J., Xia, Y., Meng, F., Yuan, J., & Zhong, Z. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0032-7 · Cited by 70
Targeting of Injectable Drug Nanocrystals
Fuhrmann, K., Gauthier, M. A., & Leroux, J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001247 · Cited by 71
Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development?
Pozzi, S., Scomparin, A., Dangoor, S. I., Ajamil, D. R., Ofek, P., Neufeld, L., Krivitsky, A., Vaskovich‐Koubi, D., Kleiner, R., Dey, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.001 · Cited by 75
Big family of nano- and microscale drug delivery systems ranging from inorganic materials to polymeric and stimuli-responsive carriers as well as drug-conjugates
Shariatinia‬, Z. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102790 · Cited by 69
Recent Photosensitizer Developments, Delivery Strategies and Combination‐based Approaches for Photodynamic Therapy†
Mariño‐Ocampo, N., Dibona‐Villanueva, L., Escobar‐Álvarez, E., Díaz, D. G., Zúñiga‐Núñez, D., Fuentealba, D., & Robinson‐Duggon, J. (2022) · Photochemistry and Photobiology · doi:10.1111/php.13749 · Cited by 74
Trends in Drug Delivery Systems for Natural Bioactive Molecules to Treat Health Disorders: The Importance of Nano-Liposomes
Cardoso, R. V., Pereira, P. R., Freitas, C. S., & Paschoalin, V. M. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122808 · Cited by 69
Targeted nanomedicine: Lessons learned and future directions
Veiga, N., Diesendruck, Y., & Peer, D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.010 · Cited by 71
Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer
Oehler, J. B., Rajapaksha, W., & Albrecht, H. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070723 · Cited by 69
Continuous-Flow Production of Injectable Liposomes via a Microfluidic Approach
Zizzari, A. T., Bianco, M., Carbone, L., Perrone, E., Amato, F., Maruccio, G., Rendina, F., & Arima, V. (2017) · Materials · doi:10.3390/ma10121411 · Cited by 69
Development and Characterization of Solid Lipid Nanoparticles Loaded with a Highly Active Doxorubicin Derivative
Stella, B., Peira, E., Dianzani, C., Gallarate, M., Battaglia, L., Gigliotti, C. L., Boggio, E. M., Dianzani, U., & Dosio, F. (2018) · Nanomaterials · doi:10.3390/nano8020110 · Cited by 69
Autonomous bacterial nanoswimmers target cancer
Zoaby, N., Shainsky‐Roitman, J., Badarneh, S., Abumanhal-Masarweh, H., Leshansky, A. M., Yaron, S., & Schroeder, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.006 · Cited by 68
Application of nanotechnology in drug delivery systems for respiratory diseases (Review)
Luo, M.-X., Hua, S., & Shang, Q.-Y. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11964 · Cited by 75
Hyperbaric oxygen regulates tumor microenvironment and boosts commercialized nanomedicine delivery for potent eradication of cancer stem-like cells
Liu, X., Ye, N., Xiao, C., Wang, X., Li, S., Deng, Y., Yang, X., Li, Z., & Yang, X. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101248 · Cited by 68
Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule
Somiya, M., & Kuroda, S. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.003 · Cited by 69
Well-defined biohybrids using reversible-deactivation radical polymerization procedures
Averick, S. E., Mehl, R. A., Das, S. R., & Matyjaszewski, K. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.030 · Cited by 70
New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage
Cern, A., Marcus, D., Tropsha, A., Barenholz, Y., & Goldblum, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.015 · Cited by 68
Self-citation
The significance of drug-to-lipid ratio to the development of optimized liposomal formulation
Chountoulesi, M., Naziris, N., Pippa, Ν., & Demetzos, C. (2017) · Journal of Liposome Research · doi:10.1080/08982104.2017.1343836 · Cited by 67
Colorectal cancer lung metastasis treatment with polymer–drug nanoparticles
Rychahou, P. G., Bae, Y., Reichel, D., Zaytseva, Y. Y., Lee, E. Y., Napier, D. L., Weiss, H. L., Roller, N., Frohman, H. A., Le, A.-T., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.008 · Cited by 68
Biodegradable hybrid block copolymer – lipid vesicles as potential drug delivery systems
Khan, S., McCabe, J. F., Hill, K. J., & Beales, P. A. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2019.11.101 · Cited by 69
Ionic Liquids in Drug Delivery
Pedro, S. N., Freire, C. S. R., Silvestre, A. J. D., & Freire, M. G. (2021) · Encyclopedia · doi:10.3390/encyclopedia1020027 · Cited by 68
Sustainable strategies for large-scale nanotechnology manufacturing in the biomedical field
Falsini, S., Bardi, U., Abou‐Hassan, A., & Ristori, S. (2018) · Green Chemistry · doi:10.1039/c8gc01248b · Cited by 67
Cell Membrane Nanotherapeutics: From Synthesis to Applications Emerging Tools for Personalized Cancer Therapy
Sevencan, C., McCoy, R. S. A., Ravisankar, P., Liu, M., Govindarajan, S., Zhu, J., Bay, B., & Leong, D. T. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900201 · Cited by 67
Multivesicular Vesicles: Preparation and Applications
Giuliano, C. B., Cvjetan, N., Ayache, J., & Walde, P. (2020) · ChemSystemsChem · doi:10.1002/syst.202000049 · Cited by 71
Drug Delivery Systems for the Oral Administration of Antimicrobial Peptides: Promising Tools to Treat Infectious Diseases
Deshayes, C., Arafath, M. N., Apaire-Marchais, V., & Roger, E. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.778645 · Cited by 75
Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
Yang, J., Wang, X., Wang, B., Park, K., Wooley, K. L., & Zhang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114525 · Cited by 67
Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery
Dumontel, B., Conejo-Rodríguez, V., Vallet‐Regí, M., & Manzano, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020447 · Cited by 74
Exploring modified chitosan-based gene delivery technologies for therapeutic advancements
Gholap, A. D., Kapare, H. S., Pagar, S., Kamandar, P. A., Bhowmik, D. D., Vishwakarma, N., Raikwar, S., Garkal, A., Mehta, T. A., Rojekar, S. V., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129581 · Cited by 69
In situ formation of biomolecular condensates as intracellular drug reservoirs for augmenting chemotherapy
Liang, T., Dong, Y., Cheng, I., Wen, P., Li, F., Liu, F., Wu, Q. Y., Ren, E., Liu, P., Li, H., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01254-y · Cited by 73
Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance
Sabir, S., Thani, A. S. B., & Abbas, Q. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1548588 · Cited by 74
Antibodies and associates: Partners in targeted drug delivery
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.004 · Cited by 69
The drug delivery field at the inflection point: Time to fight its way out of the egg
Park, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.030 · Cited by 72
Hybrid Vesicular Drug Delivery Systems for Cancer Therapeutics
Mohammadi, M., Taghavi, S., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201802136 · Cited by 67
A Biomimetic Gold Nanocages-Based Nanoplatform for Efficient Tumor Ablation and Reduced Inflammation
Xu, Q., Wan, J., Bie, N., Song, X., Yang, X., Yong, T., Zhao, Y., Yang, X., & Gan, L. (2018) · Theranostics · doi:10.7150/thno.27631 · Cited by 67
Nanopharmaceuticals: A focus on their clinical translatability
Bisso, S., & Leroux, J. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119098 · Cited by 73
Liposomal Chemotherapeutics
Gentile, E., Cilurzo, F., Marzio, L. D., Carafa, M., Ventura, C. A., Wolfram, J., Paolino, D., & Celia, C. (2013) · Future Oncology · doi:10.2217/fon.13.146 · Cited by 67
Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art
Rahman, M., Kumar, V., Beg, S., Sharma, G., Katare, O. P., & Anwar, F. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1129617 · Cited by 66
Supramolecular interaction in the action of drug delivery systems
Geng, W.-C., Jiang, Z.-T., Chen, S., & Guo, D. (2024) · Chemical Science · doi:10.1039/d3sc04585d · Cited by 71
Doxorubicin Conjugate of Poly(Ethylene Glycol)‐Block‐Polyphosphoester for Cancer Therapy
Sun, C., Dou, S., Du, J., Yang, X., Li, Y., & Wang, J. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201300091 · Cited by 66
Perfluorocarbon-loaded micro and nanosystems for medical imaging: A state of the art
Cosco, D., Fattal, E., Fresta, M., & Tsapis, N. (2014) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2014.10.013 · Cited by 66
High Throughput Nanoliposome Formation Using 3D Printed Microfluidic Flow Focusing Chips
Chen, Z., Han, J. Y., Shumate, L., Fedak, R., & DeVoe, D. L. (2019) · Advanced Materials Technologies · doi:10.1002/admt.201800511 · Cited by 66
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Zhang, D., Baldwin, P., Leal, A. S., Carapellucci, S., Sridhar, S., & Liby, K. T. (2019) · Theranostics · doi:10.7150/thno.36281 · Cited by 68
Studies of nanoparticle delivery with in vitro bio-engineered microtissues
Sun, M., Lee, J., Chen, Y., & Hoshino, K. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.06.016 · Cited by 67
Grand Challenges for Nanoscience and Nanotechnology
Parak, W. J., Nel, A. E., & Weiss, P. S. (2015) · ACS Nano · doi:10.1021/acsnano.5b04386 · Cited by 66
Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs
Howell, M., Mallela, J., Wang, C., Ravi, S., Dixit, S., Garapati, U., & Mohapatra, S. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.029 · Cited by 65
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 66
Bifunctional Submicron Colloidosomes Coassembled from Fluorescent and Superparamagnetic Nanoparticles
Bollhorst, T., Shahabi, S., Wörz, K., Petters, C., Dringen, R., Maas, M., & Rezwan, K. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201408515 · Cited by 65
Insights into composition/structure/function relationships of Doxil® gained from “high-sensitivity” differential scanning calorimetry
Wei, X., Cohen, R., & Barenholz, Y. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.04.011 · Cited by 66
Self-citation
Bioimaging of Intravenous Polymeric Micelles Based on Discrimination of Integral Particles Using an Environment-Responsive Probe
He, H., Zhang, J., Xie, Y., Lü, Y., Qi, J., Ahmad, E., Dong, X., Zhao, W., & Wu, W. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00705 · Cited by 65
In situ-prepared homogeneous supramolecular organic framework drug delivery systems (sof-DDSs): Overcoming cancer multidrug resistance and controlled release
Tian, J., Yao, C., Yang, W.-L., Zhang, L., Zhang, D., Wang, H., Zhang, F., Liu, Y., & Li, Z. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.01.010 · Cited by 65
Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?
Musazzi, U. M., Marini, V., Casiraghi, A., & Minghetti, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.016 · Cited by 67
Liposome encapsulated luteolin showed enhanced antitumor efficacy to colorectal carcinoma
Wu, G., Li, J., Yue, J., Zhang, S., & Yunusi, K. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8185 · Cited by 65
Nanomedicine: is It Lost in translation?
Greish, K. F., Mathur, A., Bakhiet, M., & Taurin, S. (2018) · Therapeutic Delivery · doi:10.4155/tde-2017-0118 · Cited by 67
Pharmacokinetics of lipid-drug conjugates loaded into liposomes
Signorell, R. D., Luciani, P., Brambilla, D., & Leroux, J. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.04.003 · Cited by 65
Surface-Functionalized Nanoparticles as Efficient Tools in Targeted Therapy of Pregnancy Complications
Zhang, B., Liang, R., Zheng, M., Cai, L., & Fan, X. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153642 · Cited by 67
Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
Li, Y., Tan, X., Liu, X., Liu, L., Fang, Y., Rao, R., Ren, Y., Yang, X., & Liu, W. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.10.003 · Cited by 65
Surface-grafted polyethylene glycol conformation impacts the transport of PEG-functionalized liposomes through a tumour extracellular matrix model
Labouta, H. I., Gomez-Garcia, M. J., Sarsons, C. D., Nguyen, T., Kennard, J., Ngo, W., Terefe, K., Iragorri, N., Lai, P. K., Rinker, K. D., et al. (2018) · RSC Advances · doi:10.1039/c7ra13438j · Cited by 64
Controlled-release nanotherapeutics: State of translation
Tan, Y., Lao, L. L., Xiong, G. M., & Venkatraman, S. S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.014 · Cited by 66
Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy
Fu, S., Zhao, Y., Sun, J., Yang, T., Zhi, D., Zhang, E. X., Zhong, F., Zhen, Y., Zhang, S., & Zhang, S. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111623 · Cited by 65
Light‐Activated Biomedical Applications of Chlorophyll Derivatives
Pucci, C., Martinelli, C., Degl’Innocenti, A., Desii, A., Pasquale, D. D., & Ciofani, G. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100181 · Cited by 64
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 67
Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies
Domingues, C., Jarak, I., Veiga, F., Dourado, M., & Figueiras, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102431 · Cited by 69
Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
Wu, M., Zhao, Y., Zhang, C., & Pu, K. (2024) · ACS Nano · doi:10.1021/acsnano.4c09800 · Cited by 65
The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine
Cisneros, E. P., Morse, B. A., Savk, A., Malik, K., Peppas, N. A., & Lanier, O. L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02954-y · Cited by 72
Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery
Zou, H., Wang, Z., & Feng, M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.014 · Cited by 65
Are PEGylated liposomes better than conventional liposomes? A special case for vincristine
Wang, X., Song, Y., Su, Y., Tian, Q., Li, B., Quan, J., & Deng, Y. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1027015 · Cited by 64
Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells
Limasale, Y. D. P., Tezcaner, A., Özen, C., Keskin, D. S., & Banerjee, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.016 · Cited by 64
A nanoparticle formulation that selectively transfects metastatic tumors in mice
Yang, J., Hendricks, W. P. D., Liu, G., McCaffery, J. M., Kinzler, K. W., Huso, D. L., Vogelstein, B., & Zhou, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313330110 · Cited by 64
Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model
Jackman, J. A., Mészáros, T., Fülöp, T., Urbanics, R., Szebeni, J., & Cho, N. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.12.377 · Cited by 64
Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue
Dancy, J. G., Wadajkar, A. S., Schneider, C. S., Mauban, J. R. H., Goloubeva, O. G., Woodworth, G. F., Winkles, J. A., & Kim, A. J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.034 · Cited by 64
Polymeric micelles for targeted tumor therapy of platinum anticancer drugs
Mochida, Y., Cabral, H., & Kataoka, K. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1307338 · Cited by 64
Harnessing the Formation of Natural Killer–Tumor Cell Immunological Synapses for Enhanced Therapeutic Effect in Solid Tumors
Im, S., Jang, D., Saravanakumar, G., Lee, J., Kang, Y., Lee, Y. M., Lee, J., Doh, J., Yang, Z. Y., Jang, M. H., et al. (2020) · Advanced Materials · doi:10.1002/adma.202000020 · Cited by 65
Drug Delivery Across the Blood–Brain Barrier: A New Strategy for the Treatment of Neurological Diseases
Jiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63

Authors: Barenholz, Y. (.
Affiliations: Hebrew University of Jerusalem (IL)
Corresponding author: Barenholz, Yechezkel (Chezy)
ORCID: Barenholz, Yechezkel (Chezy)
Venue: Journal of Controlled Release
Publisher: Elsevier BV
Published: 2012-06
Volume: 160
Issue: 2
Pages: 117-134
ISSN: 0168-3659 (ISSN-L)
DOI: 10.1016/j.jconrel.2012.03.020
OpenAlex: W1989230986
Cited by: 4,792
References: 140
Citations by year: 2026: 415 · 2025: 541 · 2024: 462 · 2023: 405 · 2022: 444 · 2021: 441 · 2020: 436 · 2019: 303 · 2018: 324 · 2017: 284 · 2016: 243 · 2015: 188 · 2014: 174 · 2013: 106 · 2012: 23
FWCI: 8.16
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Controlled Release (publishedVersion)
PubMed (publishedVersion)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: pegylated liposomal doxorubicin, PEGylated liposomes, nanotherapeutics, doxorubicin, enhanced permeability and retention effect, passive tumor targeting, liposome circulation time, remote loading, phosphatidylcholine, cholesterol, drug release, generic drug availability
MeSH terms: Antibiotics, Antineoplastic, Chemistry, Pharmaceutical, Delayed-Action Preparations, Doxorubicin, Drug Carriers, Drug Compounding, Humans, Liposomes, Solubility, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Doxil® — The first FDA-approved nano-drug: Lessons learned

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks